Brain Imaging Biomarkers in Patients With Brain Metastasis

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Dec 10, 2019

Keywords

ClinConnect Summary

This clinical trial, titled "Brain Imaging Biomarkers in Patients With Brain Metastasis," is studying how certain measurable indicators, known as biomarkers, can help predict how well patients with brain metastases will respond to radiation treatment. If you or a loved one has been diagnosed with brain metastases and is planning to receive radiation therapy, this study might be a good fit. Participants will undergo CT and MRI scans before and after their treatment to track these biomarkers and see how they relate to treatment outcomes.

To be eligible for the trial, participants need to be at least 18 years old, have a confirmed cancer diagnosis that has spread to the brain, and have at least one tumor larger than 1 cm without bleeding. Unfortunately, individuals who have had previous whole brain radiation or certain types of surgeries on their tumors cannot participate. If enrolled, participants will have regular imaging scans and will help researchers understand the potential of biomarkers in improving treatment plans for future patients. This study is currently recruiting participants, so there's an opportunity to contribute to important research in this area.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Biopsy proven primary malignancy (original biopsy is adequate as long as the brain imaging is consistent with brain metastases)
• • At least one index lesion with diameter \> 1cm and without imaging evidence of hemorrhage
• • Patients age \> 18 years of age
• • Patients planned for RT to brain metastases
• • Ability to understand and the willingness to sign a written informed consent document.
• Exclusion Criteria:
• • Previous Whole Brain Radiotherapy
• • Previous radiosurgery to the index lesion
• • Individuals unable to undergo contrasted MRI for whatever reason